The patent includes composition of the Vaxfectin adjuvant, composition of Vaxfectin-formulated vaccines, and methods for their use.
Vical president and CEO Vijay Samant said Vaxfectin was discovered through extensive screening of Vical’s lipid portfolio, and represents the new class of adjuvants which can be used for both conventional and DNA vaccines.
"We have successfully demonstrated the adjuvant’s tolerability in three Phase 1 clinical trials with Vaxfectin-formulated vaccines against pandemic strains of influenza," Samant said.